{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:07:26Z","timestamp":1792116446882,"version":"4.4.0"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Develop Med Child Neuro"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the longitudinal attainment of patient\u2010centered, function\u2010related Goal Attainment Scaling Total (GAS T)\u2010score after repeated abobotulinumtoxinA (AboBoNT\u2010A) injections over a period of up to 30\u2009months and up to 10\u2009cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>In this prospective observational study, the investigators' clinical practices recruited patients aged 2 to 17\u2009years with pediatric lower limb spasticity (PLLS). GAS T\u2010scores were assessed for each injection, and goals could be redefined at each visit; scores of 50 reflected goal achievement. Adverse events were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 210 patients in the effectiveness population, 171 had cerebral palsy and 163 were previously treated with a botulinum neurotoxin. Available Gross Motor Function Classification System levels showed that 31.3% (61 out of 195) of patients were non\u2010ambulatory. Mean (SD) cumulative GAS T\u2010score was 51.1 (9.3) across the study duration; 75.2% achieved their primary goals. GAS T\u2010scores were comparable between BoNT\u2010na\u00efve and previously treated patients and between age groups, but higher in the ambulatory than the non\u2010ambulatory subgroup. Injection guidance techniques were used in more than 70% of patients in cycles 1 to 6. Of 242 patients in the safety population, 102 reported 392 treatment\u2010emergent adverse events, including 15 reporting 35 treatment\u2010related adverse events. Adverse events were generally mild to moderate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Overall, goals were achieved as, or better than, expected in most patients. AboBoNT\u2010A was well tolerated, with a low incidence of treatment\u2010related adverse events. These results indicate that AboBoNT\u2010A is an effective treatment option, with a positive risk\u2013benefit profile, for patients with PLLS across disability levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dmcn.16428","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T03:50:05Z","timestamp":1754020205000},"page":"227-239","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and safety of\n                    <scp>abobotulinumtoxinA<\/scp>\n                    in pediatric lower limb spasticity: A phase\n                    <scp>IV<\/scp>\n                    , prospective, observational, multicenter study"],"prefix":"10.1111","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9941-7591","authenticated-orcid":false,"given":"Mark E.","family":"Gormley","sequence":"first","affiliation":[{"name":"Gillette Children's Specialty Healthcare, St.\u00a0Paul  MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Dabrowski","sequence":"additional","affiliation":[{"name":"Oakland University School of Medicine &amp; Beaumont Hospital  Grosse Point MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1855-8654","authenticated-orcid":false,"given":"Mauricio R.","family":"Delgado","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center and Scottish Rite for Children  Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Tilton","sequence":"additional","affiliation":[{"name":"LSUHSC and Children's Hospital of New Orleans  New Orleans LA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asare","family":"Christian","sequence":"additional","affiliation":[{"name":"Good Shepherd Rehabilitation Hospital  Allentown PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-243X","authenticated-orcid":false,"given":"Sarah Helen","family":"Evans","sequence":"additional","affiliation":[{"name":"Children's Hospital of Philadelphia  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Sophie","family":"Grandoulier","sequence":"additional","affiliation":[{"name":"Ipsen, Boulogne\u2010Billancourt  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumaah","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Formerly of Ipsen  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"e_1_2_11_2_1","volume-title":"Botulinum toxin treatment of muscle spasticity","author":"Magid A","year":"2007"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/354906"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-012-0192-7"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtumed.2012.12.004"},{"key":"e_1_2_11_6_1","first-page":"29","article-title":"Approach to Spasticity in general practice","volume":"2","author":"Bavikatte G.","year":"2009","journal-title":"Br J Med Pract"},{"key":"e_1_2_11_7_1","first-page":"336","volume-title":"report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society","author":"Quality Standards Subcommittee of the American Academy of N","year":"2010"},{"key":"e_1_2_11_8_1","volume-title":"National Institute for Health and Clinical Excellence: Guidance","year":"2012"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.4103\/1658-354X.121087"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-6362(99)00054-5"},{"key":"e_1_2_11_11_1","article-title":"Prescribing Information","author":"DYSPORT\u00ae (abobotulinumtoxinA)","year":"2020","journal-title":"Ipsen Biopharmaceuticals I."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins7051629"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269215508101742"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arrct.2021.100129"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.2340\/jrm.v54.2540"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/01942638.2018.1486346"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rehab.2013.02.002"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.12246"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-2830"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073816686910"},{"key":"e_1_2_11_21_1","volume-title":"Goal Attainment Scaling: applications, theory, and measurement","author":"Kiresuk TJ","year":"1994"},{"key":"e_1_2_11_22_1","unstructured":"World Health Organization.International classification of functioning disability and health.2001. Available at:https:\/\/www.who.int\/standards\/classifications\/international\u2010classification\u2010of\u2010functioning\u2010disability\u2010and\u2010health."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/09638280400018619"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.2340\/jrm.v55.6498"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2008.02045.x"}],"container-title":["Developmental Medicine &amp; Child Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dmcn.16428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T09:51:24Z","timestamp":1767606684000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dmcn.16428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/dmcn.16428"],"URL":"https:\/\/doi.org\/10.1111\/dmcn.16428","archive":["Portico"],"relation":{},"ISSN":["0012-1622","1469-8749"],"issn-type":[{"value":"0012-1622","type":"print"},{"value":"1469-8749","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"2024-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}